An Open-label, Single-arm Study to Assess the Safety Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2019
Price : $35 *
At a glance
- Drugs Cinacalcet (Primary)
- Indications Renal failure; Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 22 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 28 Apr 2016 Planned End Date changed from 1 Aug 2017 to 1 Jun 2016.